Drug intelligence / Profile preview

PBK_M2502

Development stage: Phase 3
Lead developer: Pharmbio Korea
Modality: Small Molecules
Administration: Oral

Overview

PBK_M2502 is a small molecule drug developed by Pharmbio Korea for **intestinal preparation**, which refers to cleansing of the bowel, typically before procedures such as colonoscopy. The drug is currently in Phase 3 development for this indication. Specific details about the mechanism of action, molecular target, and formulation have not been disclosed in public summaries[1][3].

Brand names: PBK_M2502
Other names: PBK_M2502

Beyond the preview

Go deeper on PBK_M2502.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBK_M2502.

Explore the full profile